SUPPORT Rx Act

The SUPPORT Rx Act creates a 3-year federal demonstration program to fund community pharmacies in providing addiction treatment for opioid and other substance use disorders. Eligible entities - including state health departments, pharmacy partnerships, and specialty treatment facilities - can apply for grants to establish or improve programs offering buprenorphine treatment, same-day low-barrier care (with minimal requirements for payment or identification), and medication-assisted therapy. Grant funds cover specific program costs like staff training, buprenorphine supply (up to 30 days), care continuity fees for patient transitions, and HIPAA-compliant technology, but may only be used for buprenorphine or overdose reversal drugs. Recipients must report annually on patient outcomes and program metrics, with results summarized in a congressional report after the demonstration ends.